NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2240
+0.0040 (+1.82%)
As of 2:24PM EST. Market open.
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.2200
Open0.2250
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2070 - 0.2250
52 Week Range0.1800 - 0.3500
Volume269,360
Avg. Volume1,343,071
Market Cap129.586M
Beta (3Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • NW Bio Moves Forward With SEC Settlement
    PR Newswire

    NW Bio Moves Forward With SEC Settlement

    BETHESDA, Md., Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC. As previously reported, the Company has been investigated by the SEC and has cooperated with the investigation. The Company has now successfully entered into a settlement agreement with the SEC under Rule 13a-15.

  • NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
    PR Newswire

    NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations

    BETHESDA, Md., Sept. 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management team with the addition of Dr. Kevin T. Duffy as Vice President, Medical Affairs and External Collaborations. Dr. Duffy also served as Scientific Affairs Strategy and Training Lead in Merck's Global Center for Scientific Affairs for Merck's immuno-oncology franchise for hematologic malignancies.  Dr. Duffy was the recipient of numerous achievement awards during his tenure at Merck.

  • Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO
    PR Newswire

    Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO

    BETHESDA, Md., June 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today highlights from Dr. Marnix Bosch's Program Update in the Industry Expert Theater presentation at the 55th annual ASCO Conference, which was publicly webcast and was posted on the home page of the Company's website at www.nwbio.com. Dr. Bosch provided an update about the Company's DCVax®-Direct Program for inoperable tumors, including new follow-up data about patient survival in the Phase I trial and new information about the next DCVax-Direct clinical trials for new disease applications. Dr. Bosch also provided an update about the Company's DCVax®-L Program for operable tumors, including the Company's progress on the road to unblinding the data from the Phase III trial in Glioblastoma, and new follow-up data from the Information Arm of patients who were not eligible for the Phase III trial because they had actual or apparent rapid tumor progression (recurrence) before they could even be enrolled in the trial.

  • NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO
    PR Newswire

    NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

    BETHESDA, Md., May 30, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit hall at the 55th Annual ASCO Convention at the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical programs. ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago.

  • NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production
    PR Newswire

    NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production

    BETHESDA, Md., May 28, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement with Cognate BioServices, Inc., resolving past matters and providing for restart of DCVax®-Direct Production. NW Bio and Cognate agreed upon revised market terms for a new Manufacturing Services Agreement for production of DCVax-Direct to be used by NW Bio in clinical trials. Production of DCVax-Direct is scheduled to start in 10 weeks. Other terms provide for a dedicated cleanroom suite, an upfront payment of $2 million for partial payment of certain past obligations, restart of new manufacturing of DCVax-Direct, and revised product manufacturing fees which incorporate certain volume discounts.

  • NW Bio Hires David Innes As Vice President, Investor Relations
    PR Newswire

    NW Bio Hires David Innes As Vice President, Investor Relations

    BETHESDA, Md., Feb. 26, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations. Innes comes to NW Bio with over 31 years of managing portfolios at major Wall Street firms, and a degree in biology.  For the last 10 years, Innes has worked as Senior Director-Investments at Oppenheimer & Co., LLC.  At Oppenheimer, Innes managed over $175 million in assets with a concentration in emerging biotech companies, including as an advisor to many shareholders at NW Bio.  Prior to Oppenheimer, he spent 20 years at UBS, including 10 years as a Vice President of Investments. Innes noted, "After decades of focusing on small to mid-cap biotech and biomedical companies, I was attracted to NW Bio by what I believe is their broad potential, due to their approach to addressing the complexity of solid tumors which comprise most cancers.

  • NW Bio Releases Voting Results From Annual Shareholders' Meeting
    PR Newswire

    NW Bio Releases Voting Results From Annual Shareholders' Meeting

    BETHESDA, Md., Feb. 8, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) — ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019.

  • Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference
    PR Newswire

    Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

    BETHESDA, Md., Jan. 25, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. Ms. Powers noted that although immune therapies have made great progress on blood cancers, the key challenge for immune therapies lies in treating solid tumors because solid tumors comprise at least 80% of all cancers and they are much more complex and variable.

  • NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds
    PR Newswire

    NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

    BETHESDA, Md. , Dec. 14, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, ...

  • NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction
    PR Newswire

    NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

    The Company will sell most of its UK property to the multi-national corporation. The Company will receive £37.5 million (approximately $47.3 million) cash payment at closing. The Company will retain ownership of 17 acres of the property, which are excluded from the sale and which the Company believes will have substantial additional value in the future.

  • ACCESSWIRE

    Growth Opportunities in Stocks Coming Off of Bottoms

    HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3 rd quarter announcements have not yet seen them baked into the share price properly. ...

  • ACCESSWIRE

    Northwest Biotherapeutics Releases Phase III Data for DCVax(R)-L and Secures New Financing

    DCVax®-L for Glioblastoma is the company's lead product for the treatment of newly diagnosed Glioblastoma. The company stock has moved from $.214 to $.29 in recent days as the company released data from its DCVax®-L phase III study.

  • Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
    PR Newswire

    Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference

    BETHESDA, Md., Nov. 19, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented by Dr. Linda Liau at the 23rd Annual Meeting of the Society for Neuro-Oncology. Patients are continuing to move through time points based on their length of time in the trial.  All of the patients were past the 1-year time point at the time of the 2017 interim data collection, and most of the patients were past the 2-year time point.  The further maturation of the data from March 2017 through October 2018 has provided an opportunity for more patients to reach later time points (3 years and beyond), and enabled a more developed picture of the "long tail" of the survival curve to emerge.  The long tail is a key focus with immune therapies.

  • NW Bio Announces $5 Million Bridge Funding
    PR Newswire

    NW Bio Announces $5 Million Bridge Funding

    The notes have a one-year maturity, subject to the Company's right to prepay the loan at any time by paying the principal plus the interest due until maturity, and subject to the holders' rights to require prepayment of the principal and accrued interest after 4 months. The Company also agreed with the Company's CEO, Linda Powers, on further extensions of the Demand Notes relating to the $5.4 million of funding which Ms. Powers provided to the Company in February, March and April of 2018 as a short-term bridge.